The retrospective analysis of colorectal carcinoma patients diagnosed in 2001-2010 and relationships between kras mutation and histopathological parameters

Colorectal carcinoma is the common cancer of the gastrointestinal tract. In both men and women, exculiding skin cancers colorectal cancer is the third most commonly diagnosed in US (1). According to the World Health Organization 2008 data, there are 1,23 million new cases of colorectal cancer each year around the world (2). KRAS is an oncogen and also a key member of EGFR which is induced by RAS-MAPK pathway. This mutation in the early stage of the develepmont of colorectal carcinoma was detected %30-%40 of these tumors. The EGFR monoclonal antibodies are alternative drugs for patients with metastatic colorectal carcinoma who had a resistance to chemotherapy and can be used in combination with other chemotherapeutic drugs. In this study we have examined the colorectal carcinoma patients respectively who were diagnosed in Mediterranean University, Patology Depertmant. Over 50 years old age with colorectal carcinoma, there were nosignificantly correlations between the parameters like tumor histological subtype, tumor location, tumor penetration depth (T), lymph node metastasis (N), distant metastases, synchronous liver metastasis and perineural invasion. We also detected KRAS gene mutations with colorectal carcinoma via using PCR-based direct sequencing to investigate the realationship between th clinicopathological characteristics. KRAS mutation has no significant correlation with patient?s age, tumor site, degree of differantiation, depth of invasion, TNM stages, musinous subtype, synchronous liver metastasis and perineural invasion. Clinical, morphological and immunohistochemical findings provide sufficient pathologic data for taking fully effective results at the new generation of antibody therapy in the treatment algorithm. Therefore, molecular genetic studies in patients with advanced stage and metastatic colorectal carcinoma has gained importance in order to increase the chances of healing and survival. Indeed, which the patient population to be benefit from treatment with anti-EGFR depends on being pre-made KRAS mutation analysis. Thus, their chances of survival will be increased with the moleculer genetic studies in larger series